

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims.

1. (Currently amended) The use of A method of inducing angioneogenesis in a subject, comprising administering to a subject a medicament containing alprostadil so as to induce for angioneogenesis in the subject.
2. (Currently amended) The use method as claimed in claim 1, wherein the angioneogenesis is employed within the framework of the treatment of chronic heart failure and/or cardiomyopathy.
3. (Currently amended) The use method as claimed in claim 1, wherein the angioneogenesis is employed within the framework of a neovascularization.
4. (Currently amended) The use method as claimed in claim 1, wherein the angioneogenesis is used to reduce the degree of fibrosis.
5. (Currently amended) The use method as claimed in claim 1 wherein the angioneogenesis is used for regression of hypertrophy.
6. (Currently amended) The use method as claimed in claim 1, wherein the angioneogenesis for revitalization of dead areas of the heart, especially after a myocardial infarction.
7. (Currently amended) The use method as claimed in claim 1, wherein the angioneogenesis is used for the treatment of advanced peripheral arterial occlusive diseases.
8. (Currently amended) The use method as claimed in claim 1, wherein the angioneogenesis is used for the treatment of diabetic angiopathy.
9. (Currently amended) The use method as claimed in claim 1, wherein the angioneogenesis is used for the treatment of systemic lung disorders, especially pulmonary fibrosis.

10. (Currently amended) The ~~use~~ method as claimed in claim 1, wherein the angiogenesis is used for the treatment of acute or chronic renal failure and glomerulonephritis.

11. (Currently amended) The ~~use~~ method as claimed in claim 1, wherein the angiogenesis is used for the treatment of acute or chronic hepatic failure.

12. (Currently amended) The ~~use~~ method as claimed in claim 1, wherein the angiogenesis is used for the treatment of cerebral infarction.

13. (Withdrawn) A medicament for angiogenesis comprising alprostadil, wherein the angiogenesis is used in a treatment selected from the group consisting of (a) treatment of chronic heart failure and/or cardiomyopathy, (b) treatment involving neovascularization, (c) treatment to reduce fibrosis, (d) treatment for regression of hypertrophy, (e) treatment to revitalize dead areas of the heart, (f) treatment of advanced peripheral arterial occlusive diseases, (g) treatment of diabetic angiopathy; (h) treatment of systematic lung disorders; (i) treatment of renal failure; (k) treatment of glomerulonephritis; (j) treatment of hepatic failure, and (l) treatment of cerebral infarction.

14. (New) The method of claim 1, wherein the medicament is administered to the subject via a central right-heart catheter with an initial dose of 2.5 ng/kg/min, which is then increased to the maximally tolerated dose (MTD) of 29 ± 1 ng/kg/min.

15. (New) The method of claim 2, wherein the medicament is administered to the subject via a central right-heart catheter with an initial dose of 2.5 ng/kg/min, which is then increased to the MTD of 29 ± 1 ng/kg/min.